Skip to main content
TipRanks
Go Ultimate75% OFF

Natera (45E) AI Stock Analysis

4 Followers
DE:45E

Natera

(Berlin:45E)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Rapid Revenue GrowthThe higher revenue outlook, supported by continued volume growth and steady ASPs, indicates broadening clinical adoption and stronger commercial execution. Sustained growth across oncology, women’s health, and organ health can expand operating leverage and reinforce Natera’s market position over the next several quarters.
Negative Factors
Profitability Remains NegativeNatera has not yet converted strong revenue growth and improved gross margins into sustainable operating profitability. Continued losses leave execution dependent on maintaining high growth and disciplined spending, while any slowdown could delay the point at which the business consistently funds expansion from earnings.

Natera (45E) vs. iShares MSCI Germany ETF (EWG)

-25%0%25%50%75%100%125%150%DE:45E+63.29%EWG+6.23%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 41.98B
Dividend Yield
―
Average Volume (3M)
59
Price to Earnings (P/E)
-253.9
Beta (1Y)
0.17
Revenue Growth
31.00%
EPS Growth
51.97%
Country
Germany
Employees
6,138
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Natera Business Overview & Revenue Model

Company Description

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromoso...

Natera Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-21.08%|Next Earnings Date:Mar 04, 2027
Earnings Call SentimentPositive

The call was strongly positive. Natera reported record testing volumes, more than 40% revenue growth excluding true-ups, accelerating MRD adoption, improving underlying gross margins, cash generation, narrowed losses, new Medicare coverage, progress toward a Japan launch, strong clinical evidence, and raised full-year guidance. The main challenges were higher planned operating expenses, near-term COGS pressure from newer products, uncertain timing for additional reimbursement decisions, and significant investment in early cancer detection before it generates revenue. These challenges were presented alongside substantial growth momentum and a long-term plan to reach $6 billion in revenue.

Positive Updates

Record Quarterly Testing Volume
Natera processed approximately 1.1 million tests in the third quarter, up more than 22% from approximately 894,000 tests in Q3 2025. Quarterly volume reached a new company record, increasing from approximately 262,000 tests in Q3 2023 to approximately 1.09 million in Q3 2026.

Negative Updates

Operating Expenses Raised and Continued Investment Required
The company increased the top end of its R&D guidance by $25 million and raised the top end of SG&A guidance from $1.225 billion to $1.3 billion. The increases reflect expanded pharma and data-service efforts, accelerated MRD trial enrollment, FIND Study costs, additional commercial initiatives, and one-time legal expenses.

Company Guidance

For 2026, Natera raised full-year revenue guidance to a range of $3.05 billion to $3.35 billion, up from $2.85 billion to $2.91 billion, an increase of $140 million at the midpoint and above $3 billion for the full year; the guide assumes steady ASPs and continued volume growth and does not include any true ups. Gross margins are expected to center at 64% to 66%, the top end of R&D was increased by $25 million, and the top end of SG&A was increased from $1.225 billion to $1.3 billion. For 2027, preliminary planning assumes the same number of units grown this year and ASP relatively steady, with a very modest assumption for true ups, gross margins in the same range as 2026, and OpEx growth in the 10% to 12% range next year, which should allow the company to continue to be cash flow generative. Natera set a goal to reach $6 billion in revenue in 2029, with several hundred million dollars of contribution from pharma and data in 2029, and said Signatera could reach $14.50 ASP versus current ASPs around $12.90, with a long term path to $2,000 ASP and beyond and a goal of 70% plus gross margins.

Natera Risk Analysis

Natera disclosed 55 risk factors in its most recent earnings report. Natera reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Natera Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:45E against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
CDNACDNA75Outperform$3.92B29.8934.08%―38.94%91.53%
BLLNBLLN70Outperform$4.37B89.199.46%―71.90%―
VCYTVCYT70Outperform$2.06B16.089.27%―17.50%311.25%
MYGNMYGN53Neutral$530.45M-4.05-40.40%―-2.63%68.56%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GHGH44Neutral$19.64B-39.44249.03%―41.69%-14.59%

* Healthcare Sector Average

Performance Comparison

0%100%200%300%400%DE:45EMYGNVCYTCDNAGHBLLNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:45E and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:45ENatera Inc.258.00100.0063.29%
MYGNMyriad Genetics5.53-1.85-25.07%
VCYTVeracyte Inc25.57-18.44-41.90%
CDNACareDx Inc74.4457.26333.29%
GHGuardant Health145.1439.7237.68%
BLLNBillionToOne, Inc. Class A91.54-18.46-16.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.